Freestone Grove Partners LP bought a new stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 44,493 shares of the specialty pharmaceutical company's stock, valued at approximately $1,611,000. Freestone Grove Partners LP owned 0.14% of Collegium Pharmaceutical at the end of the most recent reporting period.
Several other institutional investors also recently bought and sold shares of COLL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Collegium Pharmaceutical by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company's stock worth $569,000 after purchasing an additional 825 shares during the period. Millennium Management LLC boosted its stake in shares of Collegium Pharmaceutical by 248.5% in the first quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company's stock valued at $19,338,000 after purchasing an additional 461,914 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Collegium Pharmaceutical by 7.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company's stock valued at $2,120,000 after purchasing an additional 4,625 shares during the period. Jane Street Group LLC boosted its stake in shares of Collegium Pharmaceutical by 218.7% in the first quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company's stock valued at $3,926,000 after purchasing an additional 90,255 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in shares of Collegium Pharmaceutical by 3.7% in the second quarter. JPMorgan Chase & Co. now owns 72,068 shares of the specialty pharmaceutical company's stock valued at $2,131,000 after purchasing an additional 2,592 shares in the last quarter.
Collegium Pharmaceutical Stock Performance
Shares of COLL opened at $25.35 on Friday. The stock has a 50-day simple moving average of $32.96 and a 200-day simple moving average of $35.06. The company has a debt-to-equity ratio of 3.32, a quick ratio of 0.84 and a current ratio of 1.03. The stock has a market capitalization of $825.29 million, a PE ratio of 20.44 and a beta of 0.73. Collegium Pharmaceutical, Inc. has a 1 year low of $25.16 and a 1 year high of $50.79.
Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 earnings per share for the quarter, topping analysts' consensus estimates of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 5.93% and a return on equity of 91.43%. The firm had revenue of $199.88 million for the quarter, compared to analyst estimates of $199.62 million. During the same period in the prior year, the firm earned $1.68 earnings per share. The business's quarterly revenue was up 6.3% compared to the same quarter last year. On average, analysts predict that Collegium Pharmaceutical, Inc. will post 6.51 earnings per share for the current fiscal year.
Analyst Ratings Changes
Several equities research analysts recently weighed in on the stock. Zacks Research downgraded shares of Collegium Pharmaceutical from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 28th. Needham & Company LLC decreased their price target on shares of Collegium Pharmaceutical from $56.00 to $46.00 and set a "buy" rating for the company in a research report on Thursday, August 6th. Weiss Ratings downgraded shares of Collegium Pharmaceutical from a "hold (c)" rating to a "hold (c-)" rating in a research note on Tuesday, August 11th. Truist Financial upgraded shares of Collegium Pharmaceutical to a "strong-buy" rating in a research note on Monday, June 15th. Finally, Wall Street Zen lowered Collegium Pharmaceutical from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Collegium Pharmaceutical has a consensus rating of "Moderate Buy" and an average target price of $51.00.
Check Out Our Latest Research Report on COLL
Collegium Pharmaceutical Company Profile
(
Free Report)
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company's core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.
The company's principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.
Further Reading
Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Collegium Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Collegium Pharmaceutical wasn't on the list.
While Collegium Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
